Patents by Inventor Anand Devaprasath Jeyasekharan

Anand Devaprasath Jeyasekharan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PREDICTING RESPONSIVENESS TO PLK1 INHIBITION
    Publication number: 20230416836
    Abstract: The present disclosure teaches a method of predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy. In one embodiment, there is provided a method for predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy, the method comprising determining the level and/or activity of AT-rich interacting domain 1A (ARID1A) in a sample obtained from the subject.
    Type: Application
    Filed: November 9, 2021
    Publication date: December 28, 2023
    Applicant: National University of Singapore
    Inventors: Anand Devaprasath JEYASEKHARAN, Sai Srinivas UPADHYAYULA, Mai Phuong HOANG, Michal Marek HOPPE
  • Method for Predicting a Suitable Therapy
    Publication number: 20220367023
    Abstract: The invention relates to a method for predicting, selecting and screening a personalised combinatorial therapy for a patient comprising the steps of measuring a response output for each drug candidate in a sample obtained from the patient; determining a minimum set of test combinatorial therapies according to a composite experimental design, such as an orthogonal array composite design; measuring a response output and determining a relationship between the response output and the corresponding predetermined doses of the candidate drugs; and consequently deriving an optimal drug-dose combination for treating the patient.
    Type: Application
    Filed: October 16, 2020
    Publication date: November 17, 2022
    Inventors: Edward Kai-Hua Chow, Wee Joo Chng, Anand Devaprasath Jeyasekharan, Sanjay De Mel, Masturah Mohd Abdul Rashid
  • Thr51 phosphorylated HP 1? protein for the assessment of DNA damage
    Patent number: 8021851
    Abstract: This invention relates to the finding that HP1? is phosphorylated at Thr51 at an early stage in the DNA damage response in cells. Thr51P HP1? is therefore a biomarker for DNA damage which may be useful, for example, in assessing DNA damage, cancer susceptibility or the responsiveness of an individual to DNA damaging therapies.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: September 20, 2011
    Assignees: Cambridge Enterprise Limited, Medical Research Council
    Inventors: Ashok Venkitaraman, Anand Devaprasath Jeyasekharan, Nabieh Ayoub